Clinical trial

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention CAB Oral Tablets Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention CAB LA Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ABC/3TC Oral tablets Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention RPV Oral Tablets Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention HAART Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention RPV Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-04-28

PhasePHASE2

Conditions

Infection, Human Immunodeficiency Virusunresolved

HIV Infectionsunresolved

Interventions

CAB Oral TabletsDRUG

CAB LADRUG

ABC/3TC Oral tabletsDRUG

RPV Oral TabletsDRUG

HAARTOTHER

RPVDRUG

Sponsors & collaborators

ViiV Healthcarelead sponsor

Janssen Pharmaceuticalscollaborator

GlaxoSmithKlinecollaborator

Mapped research locations

MadridSpain4 MontrealQuebec, Canada4 BarcelonaSpain3 ParisFrance3 BerlinGermany3 HamburgGermany2 Los AngelesCalifornia, United States1 DallasTexas, United States1 TorontoOntario, Canada1 BirminghamAlabama, United States1 MinneapolisMinnesota, United States1 DenverColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02120352 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.